Trending Down-0.1900 (-1.8591%)
  • Bid / Lots
    9.8400/ 14
  • Ask / Lots
    10.0300/ 10
  • Open / Previous Close
    10.2200 / 10.2200
  • Day Range
    Low 9.9800
    High 10.4300
  • 52 Week Range
    Low 7.6100
    High 23.1900
  • Volume
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 10.22
02:24 ET70010.045
02:26 ET661310
02:27 ET175110.05
02:29 ET254210.04
02:31 ET73010.03
02:33 ET67610.01
02:36 ET197410.02
02:38 ET41210.015
02:40 ET20010.01
02:42 ET258210.02
02:44 ET143299.99
02:45 ET311210.04
02:47 ET89810.04
02:49 ET419710.11
02:51 ET57310.115
02:54 ET110510.08
02:56 ET216110.09
02:58 ET43910.1
03:00 ET63010.09
03:02 ET197510.095
03:03 ET264310.14
03:05 ET132210.15
03:07 ET717010.17
03:09 ET95010.14
03:12 ET471110.2
03:14 ET175010.21
03:16 ET478110.23
03:18 ET65110.225
03:20 ET112610.23
03:21 ET261510.23
03:23 ET766810.27
03:25 ET248910.24
03:27 ET177510.245
03:30 ET151010.24
03:32 ET631410.18
03:34 ET157510.19
03:36 ET181810.18
03:38 ET224310.13
03:39 ET164910.13
03:41 ET780810.12
03:43 ET251210.14
03:45 ET358810.14
03:48 ET104410.13
03:50 ET609710.13
03:52 ET728910.125
03:54 ET500410.115
03:56 ET1952210.03
03:57 ET2417710.04
03:59 ET4135410.03
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesVIR
Vir Biotechnology Inc
United StatesNRIX
Nurix Therapeutics Inc
United StatesPRTA
Prothena Corporation PLC
United StatesIMTX
Immatics NV
United StatesRCUS
Arcus Biosciences Inc
United StatesGYRE
Gyre Therapeutics Inc
As of 2024-07-20

Company Information

Vir Biotechnology, Inc. is an immunology company, which is focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions. The Company's clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). It also has several preclinical candidates in its pipeline including those targeting influenza A and B, COVID-19, respiratory syncytial virus and human metapneumovirus (RSV and MPV), and human papillomavirus (HPV). The Company's pipeline includes VIR-1949, VIR-7229, VIR-2981, VIR-8190, and HIV Cure. It also engaged in developing tobevibart, a monoclonal antibody also known as VIR-3434, and Elebsiran, an siRNA also known as VIR-2218, for the treatment and suppression of chronic HDV. Its Elebsiran is an investigational HBV-targeted siRNA that reduces HBsAg, a protein which is required for the HDV viral life cycle.

Contact Information

1800 OWENS STREET, SUITE 900SAN FRANCISCO, CA, United States 94158


Independent Chairman of the Board
Vicki Sato
Chief Executive Officer, Director
Marianne De Backer
Executive Vice President, Chief Technology Officer
Ann Hanly
Executive Vice President, Chief Scientific Officer
Jennifer Towne
Executive Vice President and Chief Business Officer
Jeffrey Calcagno

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
Revenue (TTM)
Shares Outstanding
Dividend Yield
Annual Dividend Rate
Ex-Dividend Date
Pay Date
Book Value
P/E Ratio
Price/Sales (TTM)
Price/Cash Flow (TTM)
Operating Margin
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.